We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The current financial crisis, coupled with the historic uncertainty of returns in the biotechnology industry, has significantly reduced biotech companies’ access to capital markets
